drugset / Trial / NCT05514119

A Study to Assess the Role of Fenofibrate in Preventing Ischemic Cholangiopathy After Liver Transplantation

NCT05514119

Phase 2 Terminated 6 enrolled Mayo Clinic
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the safety and effectiveness of a once-daily medication, fenofibrate (Lofibra), to prevent ischemic cholangiography (IC) in persons who were transplanted with livers donated after circulatory death (DCD).

Timeline

Start
2022-08-17
Primary completion
2024-06-30
Completion
2024-12-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Fenofibrate Small molecule 160 mg Oral

Indications

No indication recorded.